Breast Cancer Research
Papers 4727
1 page of 473 pages (4,727 results)
#1Qiong Gao (Breast Cancer Now)H-Index: 13
#1Qiong GaoH-Index: 8
Last. Anthony SkeneH-Index: 14
view all 18 authors...
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression and identify gene modules representing key biological pathways that relate to early AI therapy resistance. METHODS: Global gene expression was measured on pairs of core-cut biopsies taken at baseline and at surgery from 254 patients with ER-positive primary breast cancer ran...
#1Xiang Gu (University of Texas Health Science Center at San Antonio)H-Index: 3
#2Bingzhi Wang (CSU: Central South University)
Last. Joel E. Michalek (University of Texas Health Science Center at San Antonio)H-Index: 47
view all 11 authors...
BACKGROUND Aging is a comorbidity of breast cancer suggesting that aging-associated transcriptome changes may promote breast cancer progression. However, the mechanism underlying the age effect on breast cancer remains poorly understood. METHOD We analyzed transcriptomics of the matched normal breast tissues from the 82 breast cancer patients in The Cancer Genome Atlas (TCGA) dataset with linear regression for genes with age-associated expression that are not associated with menopause. We also a...
#1Laura A Baker (UNSW: University of New South Wales)H-Index: 4
#2Holly Holliday (UNSW: University of New South Wales)H-Index: 1
Last. Geetha Sankaranarayanan (University of Cambridge)H-Index: 1
view all 30 authors...
BACKGROUND Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset ...
#1Yara AbdouH-Index: 1
#2Kristopher AttwoodH-Index: 18
Last. Thaer KhouryH-Index: 22
view all 12 authors...
BACKGROUND African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial differences in breast cancer etiology and outcome. METHODS We examined the association of CD8+ cytotoxic T cells with clinical-pathological variables in the Women's Circle of Healt...
#1Li Yin (Third Military Medical University)H-Index: 1
#2Jiang-Jie Duan (Third Military Medical University)H-Index: 7
Last. Shi-cang Yu (Third Military Medical University)H-Index: 17
view all 4 authors...
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking....
#1Brock Humphries (UM: University of Michigan)H-Index: 9
#2Alyssa C. Cutter (UM: University of Michigan)H-Index: 1
Last. Benjamin Chiang (UM: University of Michigan)H-Index: 3
view all 22 authors...
Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tumor progression. Here, we investigated how mitochondrial fission and fusion states regulate underlying processes of cancer progression and metastasis in triple-negative breast cancer (TNBC). We enforced mitochondrial fission and fusion states through chemical or genetic approaches and measur...
#1Ritama Paul (University of Cincinnati Academic Health Center)H-Index: 1
#2Ming Luo (UM: University of Michigan)
Last. Jun-Lin Guan (University of Cincinnati Academic Health Center)H-Index: 69
view all 6 authors...
Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase, is highly overexpressed and activated in basal-like breast cancer. To understand the role of FAK in this subtype, we generated mice with con...
#1Natsuko Onishi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Meredith Sadinski (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Amita Shukla-Dave (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 30
view all 12 authors...
Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign breast lesions. However, it is unclear if they have any efficacy as prognostic imaging markers. The aim of this study was to investigate the relationship between ultrafast DCE-MRI-derived kinetic parameters and breast cancer characteristics. Consecutive breast MRI examinations between Februa...
#1Perrine Vuagnat (Curie Institute)H-Index: 1
#2Maxime Frelaut (Curie Institute)H-Index: 1
Last. Enora Laas (Curie Institute)H-Index: 4
view all 17 authors...
BACKGROUND: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). METHODS: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and trea...
1 CitationsSource
#1Florian Clatot (French Institute of Health and Medical Research)H-Index: 11
#2Anne Perdrix (French Institute of Health and Medical Research)H-Index: 4
Last. Laetitia AugustoH-Index: 2
view all 19 authors...
Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospectively compare the risk of early progression according to circulating ESR1 mutations, CA-15.3, and circulating cell-free DNA in MBC patients treated with a first-line aromatase inhibitor (AI). Patients with MBC treated with a first-line AI were prospectively included. C...
Top fields of study
Surgical oncology
Cancer research
Breast cancer